Etodolac, A Preferential COX-2 Inhibitor, does not Inhibit Platelet Aggregation in a Randomized Placebo-Controlled Trial
Journal Title: Journal of Advanced Pharmaceutical Science and Technology - Year 2013, Vol 1, Issue 1
Abstract
To date, platelet aggregation studies have not been formally evaluated in persons receiving Etodolac, a preferential cyclooxygenase-2 (COX-2) inhibitor. Our purpose was to investigate the influence of Etodolac in therapeutic (analgesic) doses (300 mg every 12h) on platelet aggregation as compared to placebo in healthy volunteers. Platelet aggregation, the primary efficacy variable in this trial, was performed according to the Born method with platelet rich plasma; it was evaluated as maximal platelet aggregation induced by 3 substances (adenosine diphosphate (ADP), epinephrine, collagen); each of these substances was used at 3 different concentrations. No significant difference in platelet aggregation as assessed by Born aggregometry was seen in volunteers treated with etodolac or placebo. Etodolac - applied in regular analgesic doses to volunteers - does not show an inhibitory effect on platelet aggregation and therefore seems an attractive analgesic substance for the perioperative setting.
Authors and Affiliations
Norbert Zoller, Anita Gähler, Priska Degiacomi, Wolfgang C Korte
Keywords
Related Articles
- EP ID EP265856
- DOI 10.14302/issn.2328-0182.japst-12-99
- Views 140
- Downloads 0
Hospital Episodes Due to Antidepressant Overdose: An Under-Utilised Source of Pharmacovigilance Data
Background: Antidepressant agents are commonly implicated in drug overdose, and the toxicological profile varies between agents. Clinical data concerning overdoses are not systematically sought or evaluated in pharmacov...
Supercritical Fluid Technology: A Review
The challenges ever faced by pharmaceutical industry is mainly due to discovery of new drugs and development of new technologies. Supercritical fluid (SCF) technology is one such technique, which has become an important...
Effect of Nonionic Surfactants and HPMC F4M on the Development of Formulations of Neuro-EPO as a Neuroprotective Agent
The purpose of this study was to investigate the effect of cremophor RH-40 and polysorbate 80 with hydroxypropyl methylcellulose (HPMC) F4M on the development of formulations of intranasal erythropoietin with low sialic...
Evaluation of SterculiaUrens Gum as Novel Carrier for Oral Colon Targeted Drug Delivery System
The purpose of the research is to evaluate Sterculiaurens gum as a carrier for oral colon targeted drug delivery system. Sterculia gum has been reported to have wide pharmaceutical applications such as tablet binder, dis...
Evaluating the Efficacy of Gene Silencing in Dopaminergic Neuronal Cells In-Vitro using Gold Nanorods (GNR) with Different Surface Properties Complexed to DARPP-32 siRNA.
Gold nanorods (GNRs) are plasmonic nanostructures by virtue of their size-dependent optical properties, offer a bionanotechnology platform in areas of bioimaging, drug delivery etc for disease diagnosis, prognosis, and t...